Answers are grounded in this paper and cite their sources.
Develops a dual-response hydrogel for improved delivery of 5-fluorouracil, suggesting enhanced safety and efficacy.
5-fluorouracil (5-FU) is widely used in clinical chemotherapy, but its non-targeted delivery causes severe systemic toxicity, and uncontrolled burst release limits therapeutic efficacy. Existing pH/temperature-responsive hydrogels for 5-FU delivery suffer from low drug loading capacity and unbalanced sustained release performance, failing to meet clinical demands. To develop highly efficient and safe drug delivery carriers, this study employed a green aqueous solution radical polymerization method. Using DEA and AMPS as functional monomers and EGDMA as a crosslinking agent, a dual-response hydrogel PDAE responsive to both temperature and pH was synthesized. Performance testing demonstrated that this hydrogel exhibits excellent mechanical and swelling properties, along with good temperature/pH sensitivity. At a DEA/AMPS molar ratio of 121:9, the gel achieved maximum 5-FU loading capacity (326.84 mg·g−1) and encapsulation efficiency (16.72%). Under physiological conditions (37°C, pH 7.4), it exhibited a cumulative release rate of 26.34%, consistent with a first-order release model. Hemolysis rate <1.9% and cell viability >87.6% indicate favorable biosafety. The optimized hydrogel addresses the limitations of current 5-FU delivery systems, providing a promising smart carrier for clinical chemotherapy with improved targeting and reduced side effects.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: